JAK1 and Alzheimer disease: Currently, three JAKi are approved for the treatment of AD: abrocitinib, a selective JAK1 inhibitor; baricitinib, which inhibits both JAK1 and JAK2; and upadacitinib, a selective and reversible JAK1 inhibitor [68].